Citius Oncology CTOR
NASDAQ CTOR
$0.69 +0.02 (+3.37%)
As of: Oct 21, 2026 · 2:06 PM EDT

Citius Oncology (CTOR) Operating Margin (2025 - 2026)

Updated

Citius Oncology (CTOR) posted Operating Margin of -583.54% for fiscal Q3 2026 (quarter ended Jun 30, 2026), up 1132.63 percentage points from the prior quarter.

Analysis

Citius Oncology (CTOR) Operating Margin (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Eli Lilly 1,137.85 Bn 1,106.43 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 618.85 Bn 537.37 Bn 17.26 Bn 28.21%
3 AbbVie 503.03 Bn 476.14 Bn 12.70 Bn 37.86%
4 Merck 368.52 Bn 322.90 Bn 12.21 Bn -3.52%
5 Novartis Ag 298.19 Bn 262.18 Bn 11.24 Bn 32.97%
6 Astrazeneca 261.33 Bn 235.02 Bn 12.86 Bn 20.57%
7 Amgen 237.14 Bn 192.53 Bn 7.24 Bn 34.95%
8 Gilead Sciences 191.35 Bn 165.54 Bn 6.22 Bn -133.21%
9 Pfizer 169.80 Bn 116.45 Bn 10.94 Bn 28.37%
10 Citius Oncology 74.83 Mn 44.42 Mn 1.00 Mn -583.54%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -583.54%
Mar 31, 2026 -1,716.17%
Dec 31, 2025 -133.17%
API Access

Citius Oncology Operating Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-margin&ticker=CTOR&period=max&api_key=YOUR_API_KEY